LANZHOU FOCI PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.78 CNY | +1.70% |
|
+4.99% | -20.21% |
| Apr. 10 | Lanzhou Foci Pharmaceutical Chairman Resigns | MT |
| Apr. 10 | Lanzhou Foci Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,988 | 3,758 | 3,615 | 5,127 | 4,764 | 4,979 |
| Enterprise Value (EV) 1 | 3,630 | 3,418 | 3,264 | 4,812 | 4,421 | 4,625 |
| P/E ratio | 53.7 x | 50.2 x | 32.3 x | 55 x | 45 x | 74.1 x |
| Yield | 0.17% | 0.82% | 1.69% | 0.1% | 0.54% | 0.31% |
| Capitalization / Revenue | 7.32 x | 5.98 x | 5.41 x | 6.27 x | 4.67 x | 4.28 x |
| EV / Revenue | 6.67 x | 5.44 x | 4.89 x | 5.89 x | 4.34 x | 3.98 x |
| EV / EBITDA | 45.3 x | 94 x | 56.6 x | 51.4 x | 40 x | 40.5 x |
| EV / FCF | -19.8 x | -14.1 x | -17.4 x | -144 x | -166 x | 76.4 x |
| FCF Yield | -5.05% | -7.08% | -5.73% | -0.7% | -0.6% | 1.31% |
| Price to Book | 2.77 x | 2.49 x | 2.27 x | 3.18 x | 2.78 x | 2.85 x |
| Nbr of stocks (in thousands) | 510,657 | 510,657 | 510,657 | 510,657 | 510,657 | 510,657 |
| Reference price 2 | 7.810 | 7.360 | 7.080 | 10.04 | 9.330 | 9.750 |
| Announcement Date | 3/21/19 | 4/23/20 | 4/15/21 | 3/15/22 | 3/30/23 | 4/9/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 544.6 | 628.8 | 668.1 | 817.6 | 1,019 | 1,163 |
| EBITDA 1 | 80.1 | 36.36 | 57.63 | 93.58 | 110.6 | 114.3 |
| EBIT 1 | 46.12 | -16.44 | 18.94 | 45.65 | 61.73 | 62.9 |
| Operating Margin | 8.47% | -2.61% | 2.84% | 5.58% | 6.06% | 5.41% |
| Earnings before Tax (EBT) 1 | 88.05 | 83.45 | 135.2 | 110.8 | 127 | 81.64 |
| Net income 1 | 74.28 | 74.85 | 112 | 93.26 | 105.9 | 67.19 |
| Net margin | 13.64% | 11.9% | 16.76% | 11.41% | 10.4% | 5.78% |
| EPS 2 | 0.1455 | 0.1466 | 0.2193 | 0.1826 | 0.2075 | 0.1316 |
| Free Cash Flow 1 | -183.3 | -242 | -187.1 | -33.49 | -26.57 | 60.54 |
| FCF margin | -33.66% | -38.49% | -28.01% | -4.1% | -2.61% | 5.2% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 52.97% |
| FCF Conversion (Net income) | - | - | - | - | - | 90.1% |
| Dividend per Share 2 | 0.0130 | 0.0600 | 0.1200 | 0.0100 | 0.0500 | 0.0300 |
| Announcement Date | 3/21/19 | 4/23/20 | 4/15/21 | 3/15/22 | 3/30/23 | 4/9/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 358 | 340 | 352 | 315 | 344 | 353 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -183 | -242 | -187 | -33.5 | -26.6 | 60.5 |
| ROE (net income / shareholders' equity) | 5.3% | 5.06% | 7.19% | 5.82% | 6.3% | 3.88% |
| ROA (Net income/ Total Assets) | 1.18% | -0.42% | 0.52% | 1.2% | 1.56% | 1.53% |
| Assets 1 | 6,276 | -17,617 | 21,677 | 7,746 | 6,781 | 4,388 |
| Book Value Per Share 2 | 2.820 | 2.960 | 3.120 | 3.160 | 3.360 | 3.420 |
| Cash Flow per Share 2 | 0.9100 | 0.8500 | 0.8200 | 0.7500 | 0.7800 | 0.8000 |
| Capex 1 | 261 | 93.2 | 123 | 32.8 | 41.5 | 22.5 |
| Capex / Sales | 47.95% | 14.81% | 18.35% | 4.01% | 4.07% | 1.93% |
| Announcement Date | 3/21/19 | 4/23/20 | 4/15/21 | 3/15/22 | 3/30/23 | 4/9/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.21% | 549M | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.19B | |
| +3.98% | 3.15B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- 002644 Stock
- Financials LanZhou Foci Pharmaceutical Co.,Ltd.